scholarly journals FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)

2019 ◽  
Vol 30 ◽  
pp. v403 ◽  
Author(s):  
K. Moore ◽  
A. Oza ◽  
N. Colombo ◽  
A. Oaknin ◽  
G. Scambia ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Folate Receptor ◽  
Phase Iii ◽  
Antibody Drug Conjugate ◽  
Folate Receptor Alpha ◽  
Receptor Alpha ◽  
Drug Conjugate ◽  
Platinum Resistant ◽  
Phase Iii Study ◽  
Antibody Drug

Safety Profile of Mirvetuximab Soravtansine, a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Patients with Recurrent Ovarian Cancer

2020 ◽  
Vol 156 (3) ◽  
pp. e15-e16
Author(s):  
Kathleen G. Essel ◽  
Lainie P. Martin ◽  
David M. O’Malley ◽  
Ursula Matulonis ◽  
Jason A. Konner ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Safety Profile ◽  
Folate Receptor ◽  
Recurrent Ovarian Cancer ◽  
Antibody Drug Conjugate ◽  
Folate Receptor Alpha ◽  
Receptor Alpha ◽  
Drug Conjugate ◽  
Antibody Drug
Sign in / Sign up

Export Citation Format

Share Document